Specific targeting of tumor cells by the creatine analog cyclocreatine. 1996

K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
AVICENA GRP INC,CAMBRIDGE,MA 02139. AMIRA INC,CAMBRIDGE,MA.

Creatine kinase (CK) an enzyme involved in cellular ATP homeostasis has been implicated in tumorigenesis. Cyclocreatine (CCr) a CK substrate analog was shown to be cytotoxic to a broad spectrum of solid tumors. We have measured and compared the CK activity and CCr sensitivity of 49 transformed and non-transformed cell lines. Among tumor cell lines, there was a strong correlation between the two (p = 0.0026, regression analysis); cell lines expressing high levels of CK (>0.10 Units/mg protein) were generally sensitive to the drug and cell lines with low CK were resistant. Tumor cell lines highest in CK and most sensitive to CCr were derived from prostate, small cell lung and neuronal tissue. The hematopoetic tumor lines tested were generally low in CK and all were resistant to CCr. Fourteen non-transformed cell lines were examined and all were resistant to the compound, including six with high levels of CK. Thus, CCr preferentially targeted tumor cells. Further, CCr inhibited tumor cell proliferation more efficiently than macromolecular synthesis indicating that, rather than exerting a general effect on energy metabolism, CCr may act on a specific pathway involved in controlling tumor cell proliferation.

UI MeSH Term Description Entries

Related Publications

K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
June 1995, Anti-cancer drugs,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
July 1989, Journal of the American College of Cardiology,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
September 1998, International journal of cancer,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
April 1993, Proceedings of the National Academy of Sciences of the United States of America,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
May 1999, Experimental neurology,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
October 1989, Biochimica et biophysica acta,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
November 1978, The Journal of biological chemistry,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
July 2022, Cancer research,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
May 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
K Martin, and E Winslow, and M Okeefe, and V Khandekar, and A Hamlin, and J Lillie, and R Kaddurahdaouk
August 2012, The Journal of clinical investigation,
Copied contents to your clipboard!